XML 36 R22.htm IDEA: XBRL DOCUMENT v3.24.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE

The following table summarizes the shares of common stock that were potentially issuable but were excluded from the computation of diluted net loss per share for the years ended December 31, 2023 and 2022 as such shares would have had an anti-dilutive effect:

  

           
   As of December 31, 
   2023   2022 
Stock options (a)   93,892    146,191 
Warrants (b)   16,725    16,725 
Unvested restricted stock   144,211    181,102 

 

(a)Shares underlying stock options assumed pursuant to the merger agreement with Precision Healing, Inc. (“Precision Healing”) in April 2022. See Note 3 for more information regarding the Precision Healing merger.
(b)Shares underlying warrants assumed pursuant to the merger agreement with Precision Healing in April 2022. See Note 3 for more information regarding the Precision Healing merger.
SCHEDULE OF REVENUE FROM PRODUCT SALES AND ROYALTIES

Revenue streams from product sales and royalties are summarized below for the years ended December 31, 2023 and 2022.

  

   2023   2022 
   For the Year Ended 
   December 31, 
   2023   2022 
Soft tissue repair products  $54,836,410   $41,653,954 
Bone fusion products   9,952,432    3,987,891 
Royalty revenue   201,000    201,000 
Total Net Revenue  $64,989,842   $45,842,845 
SCHEDULE OF PROPERTY AND EQUIPMENT

  

   Useful  December 31,   December 31, 
   Life  2023   2022 
Computers  3-5 years  $194,788   $172,154 
Office equipment  3-7 years   201,785    87,225 
Furniture and fixtures  5-10 years   304,338    258,414 
Leasehold improvements  2-5 years   134,170    19,631 
Internal use software  5 years   1,618,999    1,618,998 
              
Property and equipment, gross        2,454,080    2,156,422 
Less accumulated depreciation      (1,196,124)   (739,986)
              
Property and equipment, net     $1,257,956   $1,416,436 
SCHEDULE OF CHANGES IN FAIR VALUE FOR CONTINGENT EARNOUT CONSIDERATION

   

      
Balance at December 31, 2022  $7,166,691 
Additions   893,000 
Changes in fair value of earnout liabilities   (3,449,895)
Revaluation of earnout liability   (94,000)
Settlements   (692,795)
Balance at December 31, 2023  $3,823,001